A Phase 3 interventional study of Everolimus and Everolimus Placebo in Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 131 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carcinoma, Hepatocellular by Novartis — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Novartis.
Among the 10 studies in Carcinoma, Hepatocellular by Novartis, this one has the largest enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 4th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 10 studies in Carcinoma, Hepatocellular by Novartis is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 2
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 546 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 98 across the 10 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Carcinoma, Hepatocellular by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
This study's enrollment of 546 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior systemic treatment with sorafenib for advanced HCC and for whom their disease progressed during or after sorafenib treatment, or were intolerant to sorafenib treatment. Specifically, this can be defined as:
NOTE:
One systemic chemotherapy regimen for advanced HCC is allowed before sorafenib treatment
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
Drug: Everolimus · Other: Best Supportive Care (BSC)
Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
Drug: Everolimus Placebo · Other: Best Supportive Care (BSC)
Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
Also known as: RAD001
Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance.
Time frame: When 454 OS events were observed
Time to Tumor Progression (TTP)
TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested.
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Percentage of Participants With Disease Control Rate (DCR)
DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Time to Definitive Deterioration of ECOG Performance Score (PS) Score
Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
Time to Definitive Deterioration of EORTC QLQ-C30 Scores
The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Pharmacokinetics Assessments - Cmin
Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis.
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Pharmacokinetics Assessments - Cmax
Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis.
Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
763 patients screened, 546 randomized. At 14Jun2013 data cut-off (final analysis), 3 pts in everolimus arm, 6 in placebo arm were still on treatment. Of 9 pts, 3 receiving placebo discontinued due to disease progression. Remaining 6 completed study due to sponsor's decision to end study after final results. The LPLV was 15Oct2013.
| Milestone | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Started | 362 | 184 |
| Completed | 0 | 0 |
| Not completed | 362 | 184 |
| Withdrew: Adverse event | 61 | 14 |
| Withdrew: Withdrawal by subject | 20 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problems | 1 | 1 |
| Withdrew: Death | 13 | 5 |
| Withdrew: New cancer therapy | 2 | 0 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Sponsor's decision to end study | 3 | 3 |
| Withdrew: Disease progression | 261 | 152 |
OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance.
| Months | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Overall Survival (OS) | 7.56 (6.70 to 8.74) | 7.33 (6.28 to 8.74) |
TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested.
| Months | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Time to Tumor Progression (TTP) | 2.96 (2.79 to 4.01) | 2.60 (1.48 to 2.83) |
DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.
| Percentage of Participants | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Percentage of Participants With Disease Control Rate (DCR) | 56.1 | 45.1 |
Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead
| Months | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Time to Definitive Deterioration of ECOG Performance Score (PS) Score | 4.27 (3.32 to 4.86) | 4.47 (3.02 to 6.08) |
The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
| Months | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| Time to Definitive Deterioration of EORTC QLQ-C30 Scores | 2.86 (2.66 to 4.11) | 3.45 (2.79 to 4.17) |
Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis.
| ng/mL | Everolimus 7.5mg + Best Supportive Care (BSC) | Everolimus 5mg + Best Supportive Care (BSC) |
|---|---|---|
| Pharmacokinetics Assessments - Cmin | 16.141 ± 9.2297 | 9.318 ± 4.9705 |
Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis.
| ng/mL | Everolimus 7.5mg + Best Supportive Care (BSC) | Everolimus 5mg + Best Supportive Care (BSC) |
|---|---|---|
| Pharmacokinetics Assessments - Cmax | 47.881 ± 21.0999 | 31.592 ± 21.1622 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus + Best Supportive Care (BSC) | — | 171/361 (47.4%) | 343/361 (95%) |
| Placebo + Best Supportive Care | — | 64/182 (35.2%) | 147/182 (80.8%) |
| Event | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| AscitesGastrointestinal disorders | 13/361 | 11/182 |
| PneumoniaInfections and infestations | 18/361 | 1/182 |
| Abdominal painGastrointestinal disorders | 9/361 | 8/182 |
| AnaemiaBlood and lymphatic system disorders | 14/361 | 3/182 |
| PyrexiaGeneral disorders | 14/361 | 2/182 |
| Renal failureRenal and urinary disorders | 11/361 | 2/182 |
| HyperbilirubinaemiaHepatobiliary disorders | 5/361 | 5/182 |
| AstheniaGeneral disorders | 9/361 | 3/182 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/361 | 4/182 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 9/361 | 0/182 |
| Event | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care |
|---|---|---|
| StomatitisGastrointestinal disorders | 142/361 | 9/182 |
| Decreased appetiteMetabolism and nutrition disorders | 114/361 | 27/182 |
| Oedema peripheralGeneral disorders | 100/361 | 25/182 |
| DiarrhoeaGastrointestinal disorders | 94/361 | 25/182 |
| FatigueGeneral disorders | 90/361 | 30/182 |
| PyrexiaGeneral disorders | 86/361 | 13/182 |
| CoughRespiratory, thoracic and mediastinal disorders | 79/361 | 23/182 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 78/361 | 5/182 |
| RashSkin and subcutaneous tissue disorders | 76/361 | 16/182 |
| PruritusSkin and subcutaneous tissue disorders | 64/361 | 29/182 |
| Age, Continuous(Years) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Mean | 65.1 ± 11.70 | 64.2 ± 10.41 | 64.8 ± 11.28 |
| Age, Customized(Participants) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| < 35 years | 7 | 1 | 8 |
| >=35 - <55 years | 48 | 31 | 79 |
| >=55 - <65 years | 100 | 61 | 161 |
| >= 65 years | 207 | 91 | 298 |
| Sex: Female, Male(Participants) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Female | 59 | 24 | 83 |
| Male | 303 | 160 | 463 |
| Race/Ethnicity, Customized(Participants) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Caucasian | 192 | 110 | 302 |
| Black | 6 | 3 | 9 |
| Asian | 137 | 58 | 195 |
| Pacific Islander | 0 | 1 | 1 |
| Other | 27 | 12 | 39 |
| Weight(kg) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Mean | 69.6 ± 15.62 | 71.3 ± 17.71 | 70.2 ± 16.35 |
| Height(cm) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Mean | 167.9 ± 8.66 | 169.2 ± 8.84 | 168.3 ± 8.73 |
| BMI(kg/m^2) | Everolimus + Best Supportive Care (BSC) | Placebo + Best Supportive Care | Total |
|---|---|---|---|
| Mean | 24.5 ± 4.64 | 24.8 ± 4.99 | 24.6 ± 4.76 |
Showing the first 100 of 131 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2010, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus